Aclaris Therapeutics (ACRS) Research & Development (2014 - 2026)

Aclaris Therapeutics' Research & Development history runs 13 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• In Q1 2026, Research & Development rose 35.16% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $56.7 million (up 60.56% YoY), while the FY2025 annual figure was $52.6 million, up 56.75% from the prior year.
• Research & Development was $15.7 million for Q1 2026 at Aclaris Therapeutics, down from $16.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $26.6 million in Q4 2023 to a low of $6.0 million in Q3 2024.
• Historically, Research & Development has averaged $16.4 million across 5 years, with a median of $15.7 million in 2026.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 137.8% in 2022, then tumbled 75.05% in 2024.
• A 5-year view of Research & Development shows it stood at $21.1 million in 2022, then grew by 26.45% to $26.6 million in 2023, then sank by 66.13% to $9.0 million in 2024, then soared by 83.74% to $16.6 million in 2025, then decreased by 5.59% to $15.7 million in 2026.
• The last three Research & Development figures came in at $15.7 million (Q1 2026), $16.6 million (Q4 2025), and $13.0 million (Q3 2025), per Business Quant data.